Name | JCN037 |
---|
Description | JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively[1]. |
---|---|
Related Catalog | |
Target |
2.49 nM (EGFR), 3.95 nM (p-wtEGFR), 4.48 nM (pEGFRvⅢ)[1]. |
In Vitro | JCN037 exhibits GI50 values of 329 nM and 1116 nM in HK301 cells and GBM39 cells, respectively[1]. Western Blot Analysis[1]. Cell Line: GBM39 and GS025 cells. Concentration: 0-3333 nM Incubation Time: Result: Downregulated pEGFRvⅢ, p Akt, p-ERK, and p-S6 protein levels, significantly. |
In Vivo | JCN037 (compound 5) exhibits low oral bioavailability due to a rapid hydroxylation of the fused 1,4-dioxane ring, suggesting first pass metabolism[1]. JCN037 (compound 5, 300 mg/kg, BID) treatment provides a significant survival benefit, whereby median survival increased by 47% from 37.5 days to 55 days with 5 treatment[1]. |
References |
Molecular Formula | C16H11BrFN3O2 |
---|---|
Molecular Weight | 376.18 |